Soluble Dipeptidyl Peptidase-4 Induces Fibroblast Activation Through Proteinase-Activated Receptor-2

Shih-Yi Lee,Shao-Tung Wu,Yao-Jen Liang,Ming-Jai Su,Cheng-Wei Huang,Yu-Hsuan Jao,Hui-Chun Ku

DOI: https://doi.org/10.3389/fphar.2020.552818

IF: 5.6

2020-09-30

Frontiers in Pharmacology

Abstract:Fibroblasts are the chief secretory cells of the extracellular matrix (ECM) responsible for basal deposition and degradation of the ECM under normal conditions. During stress, fibroblasts undergo continuous activation, which is defined as the differentiation of fibroblasts into myofibroblasts, a cell type with an elevated capacity for secreting ECM proteins. Dipeptidyl peptidase-4 (DPP4) is a ubiquitously expressed transmembrane glycoprotein and exerts effects that are both dependent and independent of its enzymatic activity. DPP4 has been demonstrated to define fibroblast populations in human skin biopsies of systemic sclerosis. Shedding of DPP4 from different tissues into the circulation appears to be involved in the pathogenesis of the diseases. The mechanism underlying soluble DPP4–induced dermal fibrosis has not been clearly determined. The effects of DPP4 on murine 3T3 fibroblasts and human dermal fibroblasts were evaluated by measuring the expression of fibrotic proteins, such as α-SMA and collagen. Soluble DPP4 stimulated the activation of fibroblasts in a dose-dependent manner by activating nuclear factor-kappa B (NF-κB) and suppressor of mothers against decapentaplegic (SMAD) signaling. Blocking proteinase-activated receptor-2 (PAR2) abrogated the DPP4-induced activation of NF-κB and SMAD and expression of fibrosis-associated proteins in fibroblasts. Linagliptin, a clinically available DPP4 inhibitor, was observed to abrogate the soluble DPP4–induced expression of fibrotic proteins. This study demonstrated the mechanism underlying soluble DPP4, which activated NF-κB and SMAD signaling through PAR2, leading to fibroblast activation. Our data extend the current view of soluble DPP4. Elevated levels of circulating soluble DPP4 may contribute to one of the mediators that induce dermal fibrosis in patients.

pharmacology & pharmacy

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to explore the mechanism by which soluble dipeptidyl peptidase - 4 (sDPP4) induces fibroblast activation through protease - activated receptor - 2 (PAR2), and then leads to skin fibrosis. Specifically, the researchers hope to understand the role of sDPP4 in the process of fibroblast activation and its potential signal transduction pathways, especially whether it promotes the activation and transformation of fibroblasts by activating nuclear factor - kappa B (NF - κB) and SMAD signaling pathways, thereby participating in the pathological process of skin fibrosis. In addition, the study also explored the role of PAR2 in this process, as well as the effect of clinically available DPP4 inhibitors (such as linagliptin) on sDPP4 - induced fibroblast activation. These findings are of great significance for understanding the role of sDPP4 in fibrotic diseases and developing new treatment strategies.